Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Engage Grants Program

University of Guelph

$25,000.00

Wound healing efficacy of DispersinB: In vitro evaluation using microfluidic wound model

FY 2012-13

Summary
Kane Biotech Inc a Canadian Biotechnology Company is engaged in the development and commercialization of technologies and products to prevent and remove biofilms. DispersinB? antibiofilm enzyme-based wound spray/gel is one of the products that Kane is currently developing for both the human and veterinary applications. DispersinB inhibits biofilm formation and disperses pre-formed biofilms of major bacterial pathogens. Methicillin-resistant S. pseudintermedius (MRSP) has rapidly emerged in companion animals and MRSP infections are being reported with increasing frequency in veterinary hospitals, becoming the leading cause of pyoderma and surgical site infections in dogs. Biofilm formation is an important virulence factor of MRSP associated infections in animals. Microfluidic technology helps to precisely understand the evolution of resistance of biofilms to antimicrobial agents by creating dynamic concentration gradients, by spatial and temporal growth models, and through the bacterial motility and chemotaxis. The objective of this project is to investigate the efficacy of DispersinB using microfluidic systems against methicillin-resistant Staphylococcus pseudintermedius biofilms. By assessing the in-vitro efficacy of DispersinB alone or in combination with other antibiotic/antimicrobial agents against these MRSP biofilm isolates, the antimicrobial resistance profiles of the MRSP biofilms will be developed. The results of this project will help to determine an effective minimal concentration of DispersinB for eradicating MRSP biofilms, and the microfluidic assay would contribute to improve the clinical management of wound associated infections of companion animals.
Program
Engage Grants Program
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
435303-2012
Name nom
Neethirajan, Suresh
Department département
Engineering, School of
Organization id
24
Institution établissement
University of Guelph
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2012
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Partie
1
Nb partie
1
Application title
Wound healing efficacy of DispersinB: In vitro evaluation using microfluidic wound model
Keyword
NSERC
Application summary
Kane Biotech Inc a Canadian Biotechnology Company is engaged in the development and commercialization of technologies and products to prevent and remove biofilms. DispersinB? antibiofilm enzyme-based wound spray/gel is one of the products that Kane is currently developing for both the human and veterinary applications. DispersinB inhibits biofilm formation and disperses pre-formed biofilms of major bacterial pathogens. Methicillin-resistant S. pseudintermedius (MRSP) has rapidly emerged in companion animals and MRSP infections are being reported with increasing frequency in veterinary hospitals, becoming the leading cause of pyoderma and surgical site infections in dogs. Biofilm formation is an important virulence factor of MRSP associated infections in animals. Microfluidic technology helps to precisely understand the evolution of resistance of biofilms to antimicrobial agents by creating dynamic concentration gradients, by spatial and temporal growth models, and through the bacterial motility and chemotaxis. The objective of this project is to investigate the efficacy of DispersinB using microfluidic systems against methicillin-resistant Staphylococcus pseudintermedius biofilms. By assessing the in-vitro efficacy of DispersinB alone or in combination with other antibiotic/antimicrobial agents against these MRSP biofilm isolates, the antimicrobial resistance profiles of the MRSP biofilms will be developed. The results of this project will help to determine an effective minimal concentration of DispersinB for eradicating MRSP biofilms, and the microfluidic assay would contribute to improve the clinical management of wound associated infections of companion animals.